Home › Trials › NCT05441839

Understanding heart failure with preserved ejection fraction

UK Heart Failure With Preserved Ejection Fraction Registry

Manchester University NHS Foundation Trust · NCT05441839

This study aims to learn more about heart failure with preserved ejection fraction to find better ways to diagnose and treat people who experience symptoms like breathlessness and fatigue.

Quick facts

Study typeObservational
Enrollment10000 (estimated)
Ages18 Years and up
SexAll
SponsorManchester University NHS Foundation Trust (other gov)
Locations26 sites (Abercynon and 25 other locations)
Trial IDNCT05441839 on ClinicalTrials.gov

What this trial studies

This study focuses on heart failure with preserved ejection fraction (HFpEF), a condition where the heart can pump blood normally but still causes symptoms like breathlessness and fatigue. It aims to uncover the underlying causes of HFpEF, improve diagnostic tests, and explore new treatment options. By creating a registry that collects detailed patient data over time, the study seeks to better understand the diverse mechanisms of HFpEF and enhance personalized treatment approaches. The collaboration among multiple centers will allow for extensive data analysis and machine learning applications to refine HFpEF classification.

Who should consider this trial

Good fit: Ideal candidates include individuals diagnosed with HFpEF by qualified healthcare professionals and who have provided informed consent.

Not a fit: Patients with left ventricular ejection fraction below 40% or those with specific cardiac conditions such as infiltrative cardiomyopathy or severe valvular heart disease may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnosis and personalized treatment options for patients with HFpEF.

How similar studies have performed: Other studies have shown mixed results with HFpEF, indicating a need for more personalized approaches, making this study's focus on stratification novel and potentially impactful.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Written informed consent
2. Diagnosis of HFpEF by a cardiologist with HF expertise, or a primary care physician with HF expertise, or a heart failure nurse
3. Natriuretic peptide levels measured

Exclusion Criteria:

1. LV EF \< 40% (at screening or any previous measurement)
2. Known infiltrative cardiomyopathy (e.g., amyloid, sarcoid, lymphoma, endomyocardial fibrosis)
3. Known active myocarditis, constrictive pericarditis, or cardiac tamponade
4. Known genetic hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy
5. Known arrhythmogenic right ventricular cardiomyopathy
6. Known severe primary valvular heart disease
7. Known idiopathic, heritable or drug-induced pulmonary arterial hypertension
8. Heart transplantation or ventricular assist device
9. Complex congenital heart disease

Where this trial is running

Abercynon and 25 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Heart Failure With Preserved Ejection Fraction

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.